Pepgen (PEPG) closed at $5.26 on November 11, 2026, up 14.1% from the previous close, on volume of 14,484,661 shares (30-day average 4,520,173).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 10, 2026 | Call Spread | 20-Nov-265 : 6 C | 2,002 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
PepGen launches $125M stock offering to support clinical development
Seeking Alpha News (Tue, 10-Nov 4:46 PM ET)
PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
Business Wire (Tue, 10-Nov 4:23 PM ET)
PepGen climbs 100% as BofA upgrades on new mid-stage trial data for lead asset
Seeking Alpha News (Tue, 10-Nov 2:31 PM ET)
Why Is Penny Stock PepGen (PEPG) Up 114% Today?
TipRanks (Tue, 10-Nov 1:28 PM ET)
TipRanks (Tue, 10-Nov 11:01 AM ET)
Market Chameleon (Tue, 10-Nov 4:52 AM ET)
PepGen GAAP EPS of -$0.28 misses by $0.01
Seeking Alpha News (Tue, 10-Nov 8:43 AM ET)
PepGen Reports Positive FREEDOM2-DM1 Phase 2 Results
TipRanks (Tue, 10-Nov 8:37 AM ET)
PepGen surges on new mid-stage trial data for muscle disorder therapy
Seeking Alpha News (Tue, 10-Nov 7:41 AM ET)
PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Business Wire (Tue, 10-Nov 7:05 AM ET)
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Pepgen trades on the NASDAQ stock market under the symbol PEPG.
As of November 11, 2026, PEPG stock price climbed to $5.26 with 14,484,661 million shares trading.
PEPG has a beta of -0.32, meaning it tends to be less sensitive to market movements. PEPG has a correlation of 0.00 to the broad based SPY ETF.
PEPG has a market cap of $364.31 million. This is considered a Small Cap stock.
In the last 3 years, PEPG traded as high as $19.30 and as low as $.88.
The top ETF exchange traded funds that PEPG belongs to (by Net Assets): VTI, IBB, VXF, IWC, BUSM.
PEPG has outperformed the market in the last year with a price return of +23.5% while the SPY ETF gained +12.6%. PEPG has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +75.9% and +102.3%, respectively, while the SPY returned -1.5% and -1.3%, respectively.
PEPG support price is $4.35 and resistance is $4.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PEPG shares will trade within this expected range on the day.
